Humana Tumor Metabolome Targeting and Drug Development (Cancer Drug Discovery and Development)

Product Description Chapter 1: Tumor cell metabolic reprogramming and drug targeting (Steven B. Kanner) Chapter 2: Cancer metabolism: a nexus of matter, energy and reactive oxygen species (Paul M. Bingham, Shawn D. Stuart, Zuzana Zachar) Chapter 3: Regulating mitochondrial respiration in cancer (Teresa L. Serafim and Paulo J. Oliveira) Chapter 4: Regulation of cancer cell metabolism by hypoxia (Ashleigh Pulkoski-Gross, Nikki A. Evensen and Jian Cao) Chapter 5: Glucose metabolism and the anti-oxidative defence system in cancer cells: Options for application of ROS-based anticancer drugs (Gernot Bruchelt, Rupert Handgretinger, Mirjam Weckenmann, Talia Hahn) Chapter 6: Modulating autophagy and the "reverse Warburg effect" (Maria Vaccaro, Claudio D. Gonzalez, Silvia Alvarez and Alejandro Ropolo) Chapter 7: Metabolic adaptation in reprogrammed cancer cells (Kevin Marks and Charles Kung) Chapter 8: Targeting of PFKFB3 (Katarina Färnegårdh, Maria Shoshan, Lars Ährlund-Richter) From the Back Cover In this volume, the major metabolic alterations identified in cancer and tumor-associated cells are explored, including discussions of former and emerging approaches to drug development in targeting cancer cell metabolism.  The metabolic network in cells promotes the generation of both energy and biomass needed for them to grow, divide and differentiate.  However, the metabolism of malignant cells generally varies from that of normal cells.  These differences provide a platform for the discovery of new approaches to targeting potential vulnerabilities in cancer cells for therapeutic options  Some of the significant changes that occur involve ATP production and consumption that modulates the ATP to ADP ratio, hypoxia and the effects of reactive oxygen species on glycolysis, regulation of mitochondrial respiration, induction and suppression of autophagy, and the Warburg effect and “reverse” Warburg effect--these topics and more are discussed in this volume.   About the Author Dr. Steven B. Kanner is the Vice President of Discovery Biology at Astex Pharmaceuticals. He has been a pharmaceutical research leader with over 20 years of extensive experience in novel target identification and validation, assay development, both small molecule and antibody drug discovery, and expertise in oncology, immunology and inflammation. For more detail, please see the attached CV herewith.